← Day One Biopharmaceuticals, Inc. (DAWN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Day One Biopharmaceuticals, Inc. (DAWN)
Pharmaceutical Preparations · market cap $2.2B · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-02-15 (est.)
Phase 2
Pipeline
3
programs
Upcoming events
5
next 90d+
Dossier
Ready
cached
Day One Biopharmaceuticals (DAWN) is a ~$2.2B market cap oncology-focused biotech with 184 employees, built around tovorafenib and a chemotherapeutic agent, both in Phase 3 for low-grade glioma (LGG). The company generated $158M in revenue in 2025 while sustaining a net loss of $107M, suggesting a product already on the market funding ongoing R&D into its pipeline.
The catalyst path
- 2027-02-15 (est.)Phase 2 · Emi-Leimp 7/10
- 2027-03-01 (est.)Phase 2 · Tovorafenibimp 7/10
- 2027-05-31 (est.)Phase 2 · Tovorafenibimp 7/10
- 2027-06-15 (est.)Phase 3 · Chemotherapeutic Agentimp 9/10
- 2027-06-30 (est.)Phase 3imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Chemotherapeutic Agent | Phase 3 | Low-grade Glioma |
| Emi-Le | Phase 2 | Triple Negative Breast Cancer |
| Tovorafenib | Phase 3 | Low-grade Glioma |
Price & technical context
3-month
+78.4%
6-month
+190.6%
12-month
+201.5%
52-wk range
$5.80–$21.53
vs 50-day MA
+19.5%
vs 200-day MA
+102.2%
Realized vol
88.3%
Max drawdown
-67.2%
Daily closes through 2026-04-22. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for DAWN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.